Top Page
Biome Australia Ltd
(Sydney:BIO)
Biome Australia Ltd (BIO) vs. iShares MSCI Australia ETF (EWA)
Biome Australia Ltd Business Overview & Revenue Model
Biome Australia Ltd Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.01M | 7.24M | 4.11M | 2.32M | 866.14K |
| Gross Profit | 7.91M | 4.06M | 2.38M | 1.07M | 231.21K |
| EBITDA | -1.58M | -3.06M | -4.65M | -5.39M | -3.25M |
| Net Income | -1.67M | -3.08M | -4.54M | -5.38M | -3.16M |
Balance Sheet | |||||
| Total Assets | 8.28M | 7.56M | 8.25M | 11.09M | 1.95M |
| Cash, Cash Equivalents and Short-Term Investments | 2.87M | 2.26M | 5.49M | 9.20M | 473.50K |
| Total Debt | 1.30M | 1.15M | 467.05K | 81.00K | 504.53K |
| Total Liabilities | 5.37M | 3.97M | 1.73M | 920.00K | 997.11K |
| Stockholders Equity | 2.90M | 3.59M | 6.53M | 10.17M | 949.54K |
Cash Flow | |||||
| Free Cash Flow | -185.41K | -3.90M | -3.55M | -2.46M | -3.40M |
| Operating Cash Flow | -163.81K | -3.50M | -3.42M | -2.39M | -3.22M |
| Investing Cash Flow | -21.61K | -400.94K | -99.34K | -28.77K | -179.89K |
| Financing Cash Flow | 793.17K | 665.21K | 8.40M | 2.58M | 3.37M |
Biome Australia Ltd Technical Analysis
Biome Australia Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | 403.85 | 8.64% | ― | 60.66% | ― | ||
52 Neutral | $7.36B | -0.07 | -63.77% | 2.81% | 16.35% | 0.03% | |
46 Neutral | AU$2.23M | ― | -392.18% | ― | ― | 34.26% | |
46 Neutral | AU$14.28M | ― | -64.72% | ― | 139.19% | 33.33% | |
42 Neutral | AU$4.80M | ― | ― | ― | ― | ||
40 Underperform | AU$2.17M | ― | -45.96% | ― | ― | -26.67% | |
27 Underperform | AU$1.49M | ― | -147.32% | ― | ― | 26.09% |
Biome Australia Ltd Corporate Events
Biome Australia Limited has reported a significant increase in international sales revenue for FY25, achieving $1.5 million, a 69% rise from the previous fiscal year. The company has secured strategic distribution partnerships in Ireland, New Zealand, and Canada, positioning itself for substantial growth in FY26 by leveraging these new channels to enhance its market reach and brand recognition in the global health and wellness sector.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Ltd has announced record sales revenue for the fiscal year 2025, achieving approximately $18.4 million, marking a 41% growth compared to the previous year. The company also reported its strongest quarter to date, with Q4 sales exceeding $5 million, and record monthly sales in June of $2.1 million, indicating significant growth and positive market positioning.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has announced record sales revenue for the fiscal year 2025, achieving approximately $18.4 million, a 41% increase from the previous year. The company also reported its strongest quarter to date, with Q4 sales reaching over $5 million and June sales hitting $2.1 million, marking a 50% increase compared to the previous corresponding period. These results position Biome to meet its Vision 27 forecast of $75 million in cumulative sales for FY25-27, indicating a strong trajectory for future growth.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Ltd has announced the application for quotation of 1,042,484 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move, involving securities issued under an employee incentive scheme, is part of the company’s strategy to enhance its market presence and operational flexibility, potentially impacting its financial structure and stakeholder interests.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Ltd has announced a proposed issue of 244,442 ordinary fully paid securities, with the issuance date set for June 27, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s market presence and providing additional capital for its operations.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has announced an investor webinar scheduled for June 5th, where the company’s Managing Director, Blair Vega Norfolk, will introduce the new Chair, Geoff Sam OAM, and provide a general business update. This event reflects Biome’s ongoing commitment to engaging with investors and stakeholders, potentially impacting its market positioning by showcasing leadership changes and business strategies.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Ltd has announced the cessation of Ilario Faenza as a director, effective May 20, 2025. Faenza held significant interests in the company, including 1,534,796 fully paid ordinary shares as a registered holder and 1,421,809 shares through FDV Investments Pty Ltd, an entity he controls. This change in directorship may impact the company’s governance and strategic direction, potentially affecting stakeholders and market perception.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has announced the appointment of Geoff Sam as the new Chairman of the Board of Directors, following the resignation of Ilario Faenza. Geoff Sam, who brings significant expertise in healthcare and pharmaceutical manufacturing, is expected to play a crucial role in guiding Biome through its Vision 27 strategic plan and optimizing manufacturing processes. His leadership is anticipated to support the ongoing commercial development of Biome’s products both locally and internationally, aligning with the company’s growth objectives.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has announced the launch of two new products under its Activated Probiotics range, aimed at supporting women’s health. The Biome Her™ Pessary and Biome Perinatal™ Probiotic are designed to address specific health needs, such as vaginal microbiome balance and pregnancy-related health outcomes. These products are part of Biome’s strategy to capture a larger share of the growing women’s health market in Australia, where demand for complementary medicines is rising. The new offerings are expected to enhance Biome’s market positioning by catering to the leading demographic of complementary medicine consumers, thereby potentially increasing its market share and stakeholder value.
Biome Australia Limited reported a strong financial performance for the third quarter of 2025, with a sales revenue increase of 41% year-over-year, reaching $4.51 million. The company achieved a gross margin of 61% and recorded a net operating cash inflow of $123k, with cash receipts up 61% compared to the previous corresponding period. Biome is on track to report its first full-year net profit for FY25, marking a significant milestone in its growth trajectory. The company’s strategic expansion into international markets and the launch of its new product range, Activated Therapeutics™, are expected to further bolster its market position and stakeholder value.